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T he agent 5-fluorouracil (5-Fu) and its derivatives are widely used in the treatment of gastrointestinal,  
breast,  and head and neck cancers.  Dihydropyrimidine 
dehydrogenase (DPD) is the initial and rate-limiting 
enzyme in the catabolism of the pyrimidine bases uracil 
and thymine [1],  and is also known to be the key 
enzyme catalyzing the metabolic degradation of 5-Fu 
[2].  Patients with DPD deficiency are prone to develop 
severe 5-Fu-associated toxicity,  and the use of 5-Fu in 
such patients may even result in their death [3 , 4].  We 
report the case of an adult male with gastric cancer who 
was treated with oral 5-Fu and developed severe toxicity 
but recovered after intensive conservative treatment.
Case Report
The patient was a 63-year-old Japanese male with the 
clinical diagnosis of stage IV adenocarcinoma of the 
stomach,  with multiple metastatic sites in the liver and 
lymph nodes.  He was admitted to our hospital and was 
treated with chemotherapy consisting of oral 5-Fu 
(capecitabine,  3600 mg/day from days 1 to 14),  cispla-
tin (80 mg/m2 on day 1),  and trastuzumab (8 mg/m2 on 
day 1).  The patient was in good shape with a perfor-
mance status (PS) of 0.
On day 5,  he developed diarrhea (grade 1 according 
to the Common Terminology Criteria for Adverse 
Events version 4.0 [CTCAE v4.0]).  On day 8,  he devel-
oped grade 3 diarrhea,  grade 3 oral mucositis,  and 
grade 1 renal dysfunction.  His general condition started 
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A 63-year-old Japanese male with stomach adenocarcinoma received oral 5-fluorouracil derivative,  cisplatin 
and trastuzumab chemotherapy.  On day 8,  severe diarrhea and mucositis developed; chemotherapy was 
stopped.  On day 14,  the patient developed renal dysfunction and febrile neutropenia.  He also suffered from 
pneumonia due to Candida albicans.  Systemic symptoms improved after intensive conservative treatment.  Best 
supportive care was continued until the patient died from gastric cancer.  The dihydropyrimidine dehydroge-
nase protein level was low at 3.18 U/mg protein.  The result of DPYD genotyping revealed three variants at posi-
tions 1615 (G > A),  1627 (A > G),  and 1896 (T > C) in exons 13,  13,  and 14,  respectively.
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to deteriorate rapidly (PS 3),  preventing him from tak-
ing anything orally.  Chemotherapy was stopped on day 
9,  and total parental nutrition was introduced.
On day 14,  the patient developed grade 2 renal dys-
function and grade 3 febrile neutropenia (neutrophil 
247/mm3).  Granulocyte-colony stimulating factor,  
meropenem,  and micafungin were administered.  On 
day 22,  he developed grade 4 oral mucositis,  grade 4 
febrile neutropenia,  and grade 3 renal dysfunction.  He 
suffered from pneumonia (Fig. 1),  and a bronchoalveo-
lar lavage revealed infection by Candida albicans.  The 
anti-fungal agent was changed to amphotericin B,  and 
the patient’s systemic symptoms improved.  He was dis-
charged on day 55.  He declined to continue chemo-
therapy and received best supportive care for 3 months 
until he died from gastric cancer (Fig. 2).
Based on the patient’s clinical course,  DPD defi-
ciency was suspected.  A blood sample was obtained,  
and DPD protein was measured using an enzyme-
linked immunosorbent assay (ELISA) [5].  The DPD 
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Fig. 2　 The patientʼs clinical course.  Symptoms were assessed using CTCAE ver. 4.0.  Abbreviations were as follows: P+Tmab:  
capecitabine+cisplatin+ trastuzumab,  G-CSF,  granulocyte-stimulating factor; MEPM,  meropenem; MCFG,  micafungin; L-AMB,  liposo-
mal amphotericin B; VRCZ,  voriconazole.
Fig. 1　 Pneumonia was shown in the right upper lobe on chest 
X-ray and CT.
protein level in peripheral blood mononuclear cell 
(PBMCs) was markedly low at 3.18 U/mg protein,  and 
a diagnosis of DPD deficiency was established.  A gene 
analysis was performed as described [6].  The sequenc-
ing of all 23 exons from the patient’s sample-derived 
DNA revealed three variants in the nucleotide substitu-
tions at positions 1615 (G > A) in exon 13,  1627 (A > G) 
in exon 13,  and 1896 (T > C) in exon 14.  In addition,  
five single nucleotide polymorphisms in intron 13 
(IVS13 + 39C > T and IVS13 + 40G > A),  intron 15 
(IVS15 + 75A > G),  intron 22 (IVS22 + 55C > T),  and 
intron 23 (IVS23 – 69A > G) were detected.
Our institution’s ethical committee approved this 
clinical study (approval no. 288).  Written informed 
consent for his case to be published was obtained from 
the patient.
Discussion
DPD is the initial and rate-limiting enzyme in the 
catabolic pathway.  A partial or complete DPD defi-
ciency is associated with different degrees of 5-Fu tox-
icity,  the most frequent manifestations of which include 
neutropenia,  mucositis,  and diarrhea [7].  Although 
DPD is widely expressed in human tissues,  the liver is 
the major source of this enzyme,  harboring 80% of the 
total body supply,  with the kidneys,  spleen,  lungs, and 
marrow being minor sources [8].  DPD activities are 
high in PBMCs,  with the pattern of DPD activities 
expressed in PBMCs very similar to that found in the 
liver.  Therefore,  PBMCs are used to measure DPD 
activities [9].
The human DPD gene has been mapped to chromo-
some 1p22 and is shown to consist of 23 exons [10],  
and a variety of mutant alleles of the DPD gene has 
been reported [11].  These variants are mainly point 
variants and proteins that have missing amino acid 
sequences due to the deletion of several bases.  
However,  it is impossible to analyze all known genes,  
and DPYD genotypes and phenotypes do not coincide 
[12].  The DPD gene is transmitted to offspring by auto-
somal recessive inheritance [13-15].
Although numerous variants within the gene coding 
for DPD have been described,  only a few have been 
demonstrated to result in reduced DPD enzyme activity 
[16].  In our patient,  three point variants in exons of the 
DPYD were detected.  The 1627A > G and 1615G > A 
variants in exon 13 are missense variants,  while the 
1896 (T > C) in exon 14 is a silent variant.  The first vari-
ant,  1627A > G (I543V),  is known as rs1801159 [16].  
The frequency of I543V variants is relatively high at 
18.5%,  especially in East Asians and Americans (26.6% 
and 27%,  respectively).  In 1,070 Japanese individuals,  
21 allelic variants of DPD were identified and the fre-
quency of 1627A > G was 25.68% [17].  The clinical 
behavior of the I543V variant was favorable and the 
clinical significance was reported to be benign [18 , 19].
However,  Teh et al.  indicated that the co-existence of 
1627A > G and 1896 T > C (rs17376848) could poten-
tially be used as a predictive marker for neutropenia 
during 5-Fu treatment [20].  The second variant,  
1615G > A in exon 13 (G539R),  is known in the genome 
database as rs142619373.  The frequency of this mutant 
allele is very low at 0.7%,  and it is detected mainly in 
Africans.  Although the in vitro DPD enzyme activity of 
the G539R variant was reported to be similar to that of 
the wild-type DPD,  the clinical significance is unknown 
[21].  Further research is needed to determine whether 
the G539R variant can influence the clinical course in 
patients taking 5-Fu.
In Japan,  a total of 19 patients with DPD deficiency,  
including the present patient,  have been reported [22-
38].  Their characteristics are summarized in Table 1.  
The patients were 12 men and seven women (median age,  
64 years; range,  39-78 years).  There were 11 patients 
with colorectal cancer,  six with gastric cancer,  one with 
esophagogastric junction cancer,  and one with breast 
cancer.  Three patients received 5-Fu intravenously,  and 
the remaining 16 received oral 5-Fu derivatives such as 
S-1,  uracil/tegafur,  or capecitabine.  The median period 
from the first administration of 5-Fu to the onset of 
adverse events was 7.5 days (range 2-17 days).  DPD 
gene variant was detected in only 3 of the patients,  
including our patient.  The mortality rate from adverse 
events was approx.  21% and was not significantly asso-
ciated with age,  gender,  cancer type,  administration 
route,  or the treatment administration period.
Several methods exist to identify DPD deficien-
cy; as mentioned above,  DPD activities in PBMCs may 
be used as a marker for DPD activity in general [39 , 40].  
It was revealed that DPD levels measured by ELISA cor-
related well with DPD activities in various cancer types 
[5].  Another method,  i.e.,  the measurement of dihy-
drouracil and uracil in urine,  is simple and useful but it 
presents problems with respect to screening for carriers 
and partial deficiency [41].  The 2-13C-uracil breath test 
December 2020 DPD Deficiency with DPYD Variants 559
rapidly discriminates between normal,  partially,  and 
profoundly DPD-deficient individuals and offers a use-
ful screening method that could be applied in most 
clinical settings [42 , 43].
In a multicenter prospective cohort study,  the deter-
mination of DPD deficiency in cancer patients prior to 
or during 5-Fu treatment was shown to be beneficial in 
improving the clinical effectiveness of 5-Fu [44].  
Hernicks et al.  reported that in a cohort of 40 patients 
with heterozygous DPD deficiency treated with a 5-Fu 
dose reduced by approx.  50%,  the dose reduction did 
not reduce the effectiveness of 5-Fu-based chemother-
apy compared with patients without a DPD deficiency,  
and that the reduced dose provided significantly 
improved patient safety [45].  The cost of hospital 
admission for severe chemotherapy-related toxicity is 
significantly higher than the cost of prospective DPYD 
testing of each patient commencing fluoropyrimidine 
chemotherapy [46].  Therefore,  screening for DPD defi-
ciency would enable us to continue 5-Fu-based treat-
ments while maintaining adequate drug exposure in 
DPD-deficient patients.
As mentioned above,  although pharmacokinetic and 
pharmacogenomic tests in general have the potential to 
improve clinical outcomes by increasing efficacy and 
avoiding toxicity,  their use in routine clinical practice is 
still limited.  This also holds true for the use of DPYD 
genotyping prior to the start of treatment with 5-Fu.  In 
general,  pharmacogenomics has the potential to result 
in safer uses of drugs; unfortunately however,  these 
tests have not resulted in the clinical implementation of 
DPYD screening in the oncology field.
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Table 1　 Clinical characteristics of the 19 reported cases of Japanese patients with DPD deficiency in the literature
Reported 
year First author Age Gender Cancer site
Administration 
route of 5-Fu＊
Onset day of  
adverse events Diagnostic methods Prognosis




1998 Kobayashi K 65 Female Stomach Intravenous 17 Uracil in urine Recovered
1999 Inada T 44 Female Stomach Intravenous  2 DPD activity
Uracil in plasma
Recovered
2006 Hashimoto T 39 Male Stomach Orally  5 DPD activity Died
2008 Takaba T 72 Male Colorectal Orally  6 DPD activity
Uracil in urine
Died
2008 Kai K 75 Male Colorectal Orally  2 Uracil in urine Recovered
2010 Aragane H 70 Female Stomach Orally 14 DPD mRNA Died
2010 Iwamoto A 75 Male Colorectal Orally  3 DPD activity Recovered
2013 Tsukiyama G 64 Male Colorectal Orally  8 DPD activity Recovered
2014 Sakaguchi H 70 Male Colorectal Orally 12 DPD protein Recovered
2014 Matsumoto A 64 Female Colorectal Orally  9 DPD activity Recovered
2015 Nagai K 75 Male Colorectal Orally  5 DPD protein
Uracil in urine
Recovered
2015 Kinoshita H 51 Male Stomach Orally ND‡ DPD protein Recovered
2015 Mitake Y 78 Female Colorectal Orally 14 DPD protein Recovered
2015 Yoshida Y 73 Male Colorectal Orally 11 DPD activity
DPD gene variant
Recovered
2017 Sakata H 58 Male Colorectal Orally  7 DPD protein Died
2018 Watanabe H 57 Female Colorectal Orally  9 DPD protein Recovered
2018 Inoue H 61 Male EGJ§ Orally 14 DPD protein Recovered
2019 Our case 63 Male Stomach Orally  5 DPD protein
DPD gene variant
Recovered
5-FU＊,  5-fluorouracil; DPD†,  dihydoropyrimidine dehydrogenase; ND‡,  not described; EGJ§,  esophagogastric junction
When DPD deficiency has been demonstrated after 
chemotherapy that included 5-Fu,  a re-administration 
of 5-Fu must be re-evaluated.  The following should be 
considered: whether to reduce the amount of 5-FU and 
continue chemotherapy; whether to continue chemo-
therapy using another regimen that does not include 
5-FU; and whether to simply provide supportive care.  
Although chemotherapy without 5-Fu or best support-
ive care has been selected in most cases,  Yoshida et al.  
reported that capecitabine was administered to their 
patient with low DPD activity in incrementally increas-
ing doses every 14 days,  beginning with a single pill 
(300 mg) and then a gradual increase of the capecit-
abine dose to 1800 mg [11].  Henricks et al.  showed that 
a patient with a complete DPD deficiency could be 
safely treated with a very low dose (0.8% of original 
dose) of a 5-Fu derivative [47].
In conclusion,  we described the case of a Japanese 
patient with gastric cancer who developed severe toxic-
ity associated with three mutant alleles of the DPYD 
gene.  If severe toxicity occurs after the administration 
of 5-Fu,  it is important to consider the possibility of 
DPD deficiency and to stop chemotherapy immediately,  
and then to provide appropriate intensive supportive 
care.  In clinical practice,  DPD deficiency screening 
prior to the administration of 5-Fu should be consid-
ered to avoid severe 5-Fu toxicity.
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